Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer.
- Author:
Yun Gyoo LEE
1
;
Eunyoung LEE
;
Inho KIM
;
Keun Wook LEE
;
Tae Min KIM
;
Se Hoon LEE
;
Dong Wan KIM
;
Dae Seog HEO
Author Information
- Publication Type:Original Article
- Keywords: Small cell lung carcinoma; Thromboembolism; Cisplatin
- MeSH: Asian Continental Ancestry Group; Cisplatin; Comorbidity; Drug Therapy*; Humans; Incidence; Lung Neoplasms*; Lung*; Multivariate Analysis; Retrospective Studies; Risk Factors*; Small Cell Lung Carcinoma; Smoke; Smoking; Thromboembolism
- From:Cancer Research and Treatment 2015;47(4):670-675
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Cisplatin-associated arterial and venous thromboembolic events (TEEs) are becoming an increasing concern. In patients with small-cell lung cancer (SCLC) who are treated using cisplatin-based chemotherapy, we assume that the overall risk of TEEs is high. However, cisplatin-associated vascular toxicity in patients with SCLC has been overlooked to date. The aim of this study was to determine the incidence of TEEs in patients with SCLC and to analyze the predictors for TEE occurrence. MATERIALS AND METHODS: We retrospectively analyzed 277 patients who received chemotherapy for SCLC between 2006 and 2012. As the influence of chemotherapy on TEE occurrence developed after its initiation, a time-dependent Cox regression analysis was used to estimate the significant predictors for TEE. RESULTS: Among the 277 patients, 30 patients (11%) developed a TEE. The 3-month, 6-month, and 1-year cumulative incidences of TEEs were 5.0%, 9.1%, and 10.2%, respectively. Of 30 total TEEs, 22 (73%) occurred between the time of initiation and 4 weeks after the last dose of platinum-based chemotherapy. Approximately 218 patients (79%) received cisplatin-based chemotherapy. In multivariate analysis, cisplatin-based chemotherapy was an independent risk factor for TEE occurrence (hazard ratio [HR], 4.36; p=0.05). Variables including smoking status (common HR, 2.14; p=0.01) and comorbidity index (common HR, 1.60; p=0.05) also showed significant association with TEE occurrence. CONCLUSION: The 1-year cumulative incidence of TEE is 10.2% in Asian patients with SCLC. Cisplatin-based chemotherapy in SCLC might be a strong predictor for the risk of TEE.
